Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97440663 | 9744066 | 3 | F | 20160715 | 20131210 | 20160715 | EXP | ZA-BRISTOL-MYERS SQUIBB COMPANY-19897651 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 0.00000 | 20160715 | CN | US | ZA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97440663 | 9744066 | 1 | PS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | UNK | 21360 | FILM-COATED TABLET | |||||||||
| 97440663 | 9744066 | 2 | C | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | U | 0 | ||||||||||
| 97440663 | 9744066 | 3 | C | TENOFOVIR | TENOFOVIR | 1 | Unknown | U | 0 | ||||||||||
| 97440663 | 9744066 | 4 | C | ZIDOVUDINE. | ZIDOVUDINE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 97440663 | 9744066 | 1 | HIV infection |
| 97440663 | 9744066 | 2 | HIV infection |
| 97440663 | 9744066 | 3 | HIV infection |
| 97440663 | 9744066 | 4 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 97440663 | 9744066 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 97440663 | 9744066 | Erythema annulare | |
| 97440663 | 9744066 | Maternal exposure during pregnancy | |
| 97440663 | 9744066 | Photosensitivity reaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |